It is an immutable law in business that words are words, explanations are explanations, but only performance is a reality. And Malvinder Mohan Singh, CMD of Ranbaxy Laboratories Limited, has enabled the company to achieve stupendous performance in a very short span of time. That has proved him a worthy son of a worthy father. Son of the iconic Parvinder Singh who turned Ranbaxy from a middling company into a growing MNC giant, Malvinder has infused fresh blood into the country's largest pharmaceutical company that also ranks among the top ten generic players in the world.

Responsible for the entire global operations of the company, which spans in 44 countries and covers wide range of products ranging from pharmaceuticals, APIs and manufacturing locations in 7 countries, Malvinder today is a heroic and revered figure. No wonder, his strength of character is well appreciated, for he earned his position by dint of his talent, hard work and devotion to his goal. A graduate in economics from the prestigious St. Stephen's college, Malvinder also holds a Masters degree in Business Administration (MBA) from the Fuqua School of Business, Duke University, USA.

Malvinder joined Ranbaxy in 1998 and since then he hasn't looked back. Believing that learning is a slow, steady and painstaking effort, Malvinder, over the years imbibed business nuances while working in diverse areas of operations like general management, sales and marketing, finance and business development. Prior to being elevated to the present position, Singh successfully led the company's India operations as regional director and also played a key role in establishing the company's presence overseas since, 80 per cent of Ranbaxy's business is international and only 20 per cent is domestic.

Malvinder and his family are the largest shareholders in Ranbaxy, Fortis Healthcare, Escorts Heart Institute & Research Centre and SRL Ranbaxy, which together constitute the largest health care group in India. He serves on the Boards of these companies and is Chairman of Religare Enterprises, India's leading integrated financial services provider. Prior to his current position at Ranbaxy Laboratories, he was President, Pharmaceuticals for the same company. In this position he had responsibility for the company's global operations. As the new CMD, he assumes complete operational responsibility for the company and will be focusing on spearheading Ranbaxy's growth to its target of achieving USD 5 billion of global sales by 2012.

With major focus in the areas like urology, anti-infectives, respiratory, anti-inflammatory and metabolic disorders, Ranbaxy has grew from $150 million revenue in 1993 to $1 billion in 10 years. Understandably, he is the driving force behind the company's stupendous growth in recent years. What's makes Malvinder different from others? It's probably his new approach to international business and his ability to take fresh initiatives, risks and lead a strategic team, which has added charisma to his professional life. A member of the National Council for the Confederation of Indian Industries (CII), Malvinder is also the Co-Chairman of the National committee on Intellectual Property Rights. Recently, he was nominated to the forum of 'Young Global Leaders', World Economic Forum, and have been playing crucial role at various other forums. An adept golfer and leader, he features on Forbes 2007's list of Billionaires as the 488th richest man in the world. Malvinder's dynamic leadership is sure to give Ranbaxy a new direction.